Today LeapFrog Enterprises, Inc. (NYSE: LF), education innovation leader and creator of award-winning learning products, announces its Tag. Give. Read. program to help more U.S. children learn and love to read. LeapFrog laid the program groundwork with a 2009 donation of $1.5 million in Tag Reading Systems and books to the classrooms of more than 10,000 U.S. Kindergarten students. By the end of the school year, 99% of teachers said they would recommend Tag Readers to other teachers and to parents, because their students’ attitudes about reading and reading skills both had improved.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/leapfrog/46266/
After an unexpected diagnosis of atrial fibrillation (AFib), a type of irregular heart beat they had never heard of before, daytime TV star Susan Lucci and her husband Helmut Huber learned he is one of the estimated 2.3 million Americans living with the condition, which can increase the risk of stroke nearly five-fold. The couple, who have spent more than a decade working with their doctor to help minimize Helmut’s stroke risk, today announced they have partnered with Boehringer Ingelheim Pharmaceuticals, Inc., National Stroke Association and StopAfib.org to launch a new national education program to improve awareness of AFib and its increased risk of stroke.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/boehringer-ingelheim/46196/
Social media is changing the way people find jobs, but according to the latest Emerging Workforce® Study by SFN Group, most companies are out of step. In fact, less than one-fourth have a formal social media strategy in place, and of those, only one-third say they’ve had success.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sfngroup/46057/
Getting ready to meet with a prospective employer? Leave your cat suit, pajamas and crazy hat at home. In a recent survey, OfficeTeam asked human resources (HR) managers to recount the strangest interview outfits they had heard of or seen.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/roberthalf/45118/
http://www.goherefor.me/now/941
When one of my facebook contacts grabbed my attention by reporting 4 figure days on a consistent basis....
I had to know how to do it and fast.
I put all the details on my blog -
http://www.goherefor.me/now/941
Red light cameras saved 159 lives in 2004-08 in 14 of the biggest US cities, a new analysis by the Insurance Institute for Highway Safety shows. Had cameras been operating during that period in all large cities, a total of 815 deaths would have been prevented.
In the days when “tweets” were bird sounds and a “text” was a book, workplace blunders had a limited audience. Now, however, these missteps can receive broad exposure -- with unhappy consequences: Three out of four (76 percent) human resources (HR) managers polled by Robert Half said technology etiquette breaches can affect a person’s career prospects.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/roberthalf/46961/
In a moving and inspiring memoir, told with genuine humility, a warrior who wanted to be strong to be good, discovers that he had to be good to be strong. The result is a lesson for us all, the heart and fist together are more powerful than either one alone. Learn more about this book here, http://www.theheartandthefist.com/ and its author here, http://www.theheartandthefist.com/bio Non-Fiction, Memoir
The ultimate battle. The ultimate love. Jenn is betrayed by one who was once bound to protect her, causing her to doubt all she had held as true. To survive, Jenn must find the courage to trust herself, and her heart, in Crusade by bestselling Wicked authors, Nancy Holder and Debbie Viguie. Learn more about this book here, http://bit.ly/cvH4pF and its authors here, http:///www.nancyholder.com and http://www.debbieviguie.com YA
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
Bayer HealthCare’s Consumer Care division announced today the introduction of Bayer® Advanced Aspirin, the next generation of aspirin for pain relief. Using the patent-pending Pro-Release™ Technology, Bayer Advanced Aspirin is clinically proven to relieve tough pain twice as fast as previous Bayer® Aspirin tablets.
With the introduction of aspirin in 1899, Bayer offered one of the first widely accessible analgesics, or pain relievers, to consumers. Today, Bayer's overall global Aspirin business continues to grow, and had double-digit, year-on-year sales growth in Q1 2011. Yet, while Bayer continues to be a leader in the category, for many U.S. consumers, Bayer Aspirin is primarily synonymous with cardiovascular use. Now, through a combination of technological innovation and rich analgesic heritage, Bayer is introducing a new standard in aspirin for tough pain relief with Bayer Advanced Aspirin.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bayer/50414/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
